Breast cancer ecotypes could guide personalised treatment
By analysing breast cancer biopsies from patients at Sydney hospitals, an international team led by the Garvan Institute of Medical Research has revealed more than 50 distinct cancer, immune and connective cell types and states, which could assign breast cancers to one of nine cancer ‘ecotypes’ — each of which was associated with a different cancer prognosis. Their results have been published in the journal Nature Genetics.
Breast cancer in unprecedented detail
Breast cancers are currently classified into three clinical subtypes (luminal, HER2+ and triple negative), based on specific receptors they do or do not produce. While these subtypes are used to estimate prognosis and guide treatments, not all breast cancers respond to this strategy, with the disease still claiming 3000 lives in Australia alone each year.
“Tumours are not made up of a single cell type, but rather a complex mix of cancer, immune and connective tissue cells that all play a role in tumour progression and prognosis,” said Associate Professor Alex Swarbrick, Head of the Tumour Progression Lab at Garvan and senior author of the study.
“Current methods for classifying breast cancers only provide a limited picture of the complex biology contained in the tumours,” added Garvan’s Sunny Wu, co-first author of the study. “Classifying breast cancers based on their entire composition of cells can provide a new and comprehensive view of a cancer. We wanted to develop an accessible framework for this.”
Using cellular and spatial genomics technologies, which analyse individual cells and map their location within a tissue sample, the researchers assessed breast cancer biopsies from 26 patients at Sydney hospitals, including St Vincent’s Hospital Sydney and Chris O’Brien Lifehouse. These samples were analysed in The Garvan-Weizmann Centre for Cellular Genomics.
“We looked at the complete cell profile of each breast cancer sample and revealed more than 50 different cell types or cell states that were present,” said Garvan’s Ghamdan Al-Eryani, co-first author of the study. “We then analysed publicly available data from thousands of breast cancer patients and by assigning the new cell types and states discovered nine recurring patterns, which we define as ‘ecotypes’.”
“Each of these ecotypes directly corresponded with a different clinical outcome in patients, which is why we think they may help reveal which treatment a tumour will best respond to,” added co-first author Dr Daniel Roden, also from Garvan.
Developing a new diagnostic approach
“This study has shown us how crucial the complete cellular profile of tumours is to advancing breast cancer research aimed at personalised treatments,” Assoc Prof Swarbrick said. The team will next explore how their ecotyping method could be introduced in a clinical diagnostics pipeline, as a predictive test for personalised treatment.
“One thing that is characteristic about each ecotype is their profile of immune cells,” Assoc Prof Swarbrick said. “We expect that this would relate to a cancer’s response to immunotherapy, and identify patients that could benefit from this treatment.
“For instance, we found one breast cancer ecotype that uniquely has a high number of infiltrating lymphocytes, which are the target of current immunotherapies, and low levels of cells that we know to suppress lymphocytes. We would predict that those patients would respond well to immunotherapy, which is highly effective in some cancers, such as melanoma or lung cancer, but has a response of less than 10% in breast cancer patients.”
The data generated during the study is publicly available to researchers and forms part of the Breast Cancer Cell Atlas, an ambitious project to catalogue a million individual cells from 200 patient breast tumours and provide the most comprehensive cellular view of breast cancer yet.
To fast-track time to market and gain a competitive edge, pharmaceutical development companies...
An existing drug — used to treat constipation — may be able to boost our ability to...
KNT-127 — a drug that targets delta opioid receptors — can reduce pro-inflammatory...